Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FeMike at one time thought:
April/May optimistic.
June/July realistic.
August pessimistic.
FWIW
Spot on!
Want to know how the “man” makes it hard to move cancer therapy towards a cure? Chiocca, Chen, Ling and Reardon are exhibits one through four.
Balderdash!
Brilliant!
Bloody hell!
Dummkopf, the JAMA article did disclose conflicts of interest.
There were many more errors in the Chen Ling Reardon Chiocca Thanksgiving hit article timed to detract from NWBO’s then imminent MAA submission.
There was Reardon’s incorrect statement that idh status was not tracked.
There was Chiocca’s misstatement that 90% of placebos crossed over. (They thought they could get away with this, because in one, just one, of Dr.Liau’s dozens of interviews, she made this inadvertent misstatement, when everything else stated, published and peer reviewed was correct. It is no surprise that Exwannabe had the exact same childlike agenda on this.)
There was Chen’s error that mistated NWBO supposedly excluded all the patients with tumors that could escape treatment.
Etc.
There was also failure by the authors to correctly disclose their conflicts of interest.
The non-peer review is so error ridden it never should have seen the light of day, instead it was timed to slime DCVax-l ahead of NWBO’s MAA submission. This unfairly impacted not only any potential NWBO PPS momentum, but, more importantly, it was meant to put a false spotlight on DCVax-l at a time it was about to be reviewed by regulators.
90% of the production space at Sawston is NWBO’s/Flaskwork’s not Advent/Toucans, and Advent is a contractor for NWBO. Maybe you should just rest a while.
Flaskworks is very valuable as it will soon, under its patents, following Advent, commercially make DCVax, if approved, which will also be protected under biologic exclusive use and data exclusive use, as well as combination protection.
And DCVax-Direct has patent protection out to 2036.
You’ll be ok. Asking for help is your first step.
The delta for both nGBM and rGBM are more than sufficient for valuation purposes, particularly after Eden increases profit margin, and as your amnesia constantly returns; reminder, Flaskworks is NWBO, not Toucan/Advent.
I am one of those people that thinks NWBO essentially used regulator consultants and former regulators to project what the mhra (and other authorities) would require in an RFI, and that’s one primary reason it took so long to submit. In other words, they tried very hard to reduce the chance that a major RFI (or any RFI at all) would be issued.
That said, like you, I agree timeline expectations must be tempered, but at the same time, believe shorts are ill-advised to take any further positions, because we’ve entered the window for potential decision. The odds increase every day that a decision might be published.
Quit suggesting people assassinate other people.
Right, as an adjuvant.
https://www.cancerresearch.org/cancer-types/skin-cancer
Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma.
That’s a new word for me.
Abstruse
MHRA:
Yes, ever since the 80 days passed, there is a chance that any business day could provide a decision. It gets more likely as each day passes.
He did Gary. 150 + 120 is 270.
The trial remained blinded prior to the protocol change. This happens quite often in trials. Not “Ex post facto.”
That Journal, BJC, only has an impact factor of 9.
Whereas
That’s a shoddy review, not JAMA.
That is proven wrong by the recurrent data which used no chemo in the recurrent trial.
Pay attention instead of plagiarizing shoddy reviews.
The DCVax-l rGBM trial does not use chemo. Like almost all recurrent GBM trials, the DCVax-l rGBM trial starts after chemo has failed.
Dummkopf.
This helps show MOA and why checkpoint inhibitors could help:
1. T-cells infiltrate the tumor.
2. Obviously reduce t-cell exhaustion.
3. Reduce tumor assisted macrophages (TAM) in the tumor microenvironment.
BTW, you were right, your MHRA link is more up to date.
Digging into the Twitter thing further, I found that your MHRA link was still first, not MHRA Twitter.
Maybe, but I think the next list, for the last half of March, gets published on Monday.
I was thinking of MarauderWarlock’s post instead. Apologies.
Thinking about this just announced policy more, I wonder if it might (also) prevent intimidation by third parties.
Just an observation. MHRA converted from publishing their product marketing approvals from every month to every 14 days on October 1, 2022.
BTW, I think this might be the better link.
https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024
I was talking to somebody about the photographer’s picture of his dying daughter in agony from cancer.
There was a deck of cards nearby.
I said, imagine this deck of cards could cure cancer if used in the right way, but you need the whole deck.
The fundamental problem is that large pharma does not want to cure cancer. They instead see massive economic opportunity by dividing the cards up amongst all the BP. I started throwing cards down individually and in clusters.
The person I was speaking with said, I get it, I get it.
That is their cynical economic model.
I’m not certain. If they already submitted or extremely close (fda) and CRL is ready, then maybe artisan first here, but I kinda doubt it. I think commercial artisan serves a purpose at Advent — parallel testing Eden.
NWBO is so close to the vest.
Not my wheelhouse.
Doc or anybody else, the press release on the Eden prototype being assigned to a device manufacturer was a bit vague on dates.
It is my contention that this was done earlier than the beginning of February. I think it was probably done by at least December 20, if not earlier.
I assume the contractor considers this high priority. I assume Flaskworks and Dr. Bosch visit often to consult and provide feedback.
I assume the device manufacturer is efficient at what they do.
Sure would like to know who it is, but I’d reckon nwbo starts testing the commercial version by sometime in June.
It sounds more immediate.
CRL/cognate might be ready. We don’t know.
I could guess, but…. better not.